Regentis Biomaterials Ltd. (RGNT) Stock Price & Analysis
Regentis Biomaterials Ltd. (RGNT) closed at USD 1.28 on Friday, October 23, 2026, down 8.57% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.4; the Oct 23, 2026 session ranged USD 1.28–1.42 on volume of 18,431 shares. Market capitalization is $8.99M, with a 52-week range of USD 1.23–15.5 (ASE). Source: Nexqual, retrieved October 24, 2026 at 10:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RGNT.md
Key facts (RGNT)
- Analysts: None (1 analysts), mean target USD 10 (range 10–10).
- Total return with dividends: 1Y -82.9% vs S&P 500 +13.4%; 5Y -82.9% vs S&P 500 +76.9%.
Analysts (RGNT)
Consensus None, 1 analysts; mean target USD 10 (low 10, high 10).
Total return (dividends reinvested) (RGNT)
| 1Y (from 2025-12-04) | 5Y (from 2025-12-01) | |
|---|---|---|
| Total return | -82.9% | -82.9% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | — | — |
| Volatility (annualized) | 239.6% | 142.7% |
| Max drawdown | -86.4% (Jun 2026→Oct 2026) | -82.9% (Dec 2025→Oct 2026) |
RGNT suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Baxter Healthcare | “July 24, 2008, we entered into a supply agreement, or the Supply Agreement, with Baxter Healthcare Corporation, or Baxter, and Teva Medical” |
Quoted from the company's 20-F filed Feb 24, 2026.
RGNT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Mar 2026) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2026) | $-0.68 | $0.00 | — | $0 | 1 |
| Next fiscal year (ends Dec 2027) | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 10:24 UTC)
| Price | USD 1.28 |
|---|---|
| Change | ▼ 8.57% (down) |
| Previous Close | USD 1.4 |
| Open | USD 1.42 |
| Day Range | USD 1.28 – 1.42 |
| 52-Week Range | USD 1.23 – 15.5 |
| Volume | 18,431 shares |
| Market Cap | $8.99M |
| Exchange | ASE |
Technical Analysis (RGNT)
Nexqual's technical model rates RGNT "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 10:24 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.82 (oversold) |
| vs SMA50 | Below (USD 1.85) |
| MACD | -0.14 (negative) |
Analyst Ratings (RGNT)
Wall Street analysts rate RGNT "None" based on 1 analysts, with a mean price target of USD 10 (range USD 10–10), per Nexqual as of October 24, 2026 at 10:24 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 10 |
| High Target | USD 10 |
| Low Target | USD 10 |
Earnings (RGNT)
Source: Nexqual, October 24, 2026 at 10:24 UTC.
Financials & Fundamentals (RGNT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0 |
| Current Ratio | 5.62 |
| Total Cash | $8.95M |
| Total Debt | $29,000 |
Source: Nexqual, October 24, 2026 at 10:24 UTC.
Financial Health Score (RGNT)
Nexqual rates Regentis Biomaterials Ltd.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 10:24 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $9M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$4M (TTM) |
| Efficiency | Mixed — No data |
Ownership (RGNT)
| Insider Ownership | +14.04% |
|---|---|
| Institutional Ownership | +25.19% |
| Shares Outstanding | 7.02M |
| Float | 4.26M |
| Short % of Float | +0.07% |
Source: Nexqual, October 24, 2026 at 10:24 UTC.
Leadership (RGNT)
Regentis Biomaterials Ltd. is led by Ehud Geller, CEO & Executive Chairman, per Nexqual as of October 24, 2026 at 10:24 UTC.
| CEO & Executive Chairman | Ehud Geller |
|---|---|
| Co-Founder & Chief Scientific Officer | Dror Seliktar |
| CFO & Chief Business Officer | Ori Gon |
Major Backers & Investors (RGNT)
Notable institutional backers of Regentis Biomaterials Ltd. include Rosalind Advisors, Inc., Warberg Asset Management LLC, Jane Street Group, LLC, according to Nexqual as of October 24, 2026 at 10:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rosalind Advisors, Inc. | 9.99% |
| Warberg Asset Management LLC | 1.24% |
| Jane Street Group, LLC | 0.62% |
| Renaissance Technologies | 0.19% |
Source: Nexqual, October 24, 2026 at 10:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMTS | Kestra Medical Technologies, Lt | USD 28.76 | ▲ 1.55% |
| XRAY | DENTSPLY SIRONA Inc. | USD 9.43 | ▼ 0.74% |
| LMAT | LeMaitre Vascular, Inc. | USD 84.45 | ▼ 1.03% |
| ATRC | AtriCure, Inc. | USD 58.97 | ▼ 0.56% |
| WRBY | Warby Parker Inc. | USD 25.91 | ▲ 0.93% |
| PLSE | Pulse Biosciences, Inc | USD 53.02 | ▲ 0.65% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 10:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt